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(10/20), EZ/S 40 mg (10/40), and EZ/S 80 mg (10/80) through Periods 1-4; and (3) EZ/S
20 mg titrated to EZ/S 40 mg (for Periods 2 and 3), then EZ/S 80 mg for Period 4. Primary
endpoint was % change from baseline in LDL-C after the initial 6-week period. Second-
ary endpoints included % change from baseline in LDL-C to ends of Periods 2, 3, and 4;
and HDL-C to ends of Periods 1, 2, 3, and 4. Safety measurements were clinical and lab-
oratory adverse events including ALT or AST _3x upper limit of normal (ULN), CK _10x
ULN.
Results: Baseline LDL-C and HDL-C levels were comparable between treatment groups.
At the end of Period 1, mean LDL-C reduction and mean HDL-C increase were signifi-
cantly (p_0.01) greater for the EZ/S 10 mg and EZ/S 20 mg groups compared with the
A10 mg group (see Table). At the end of Period 4, comparing maximum doses, EZ/S 80
mg was superior to A80 mg in LDL-C reduction (–59.4 vs –52.5) and HDL-C increase
(12.3 vs 6.5). 
Conclusion: Greater LDL-C reduction and HDL-C increase can be attained by treating 
with EZ/S compared with atorvastatin. Treatments with EZ/S and A were well-tolerated.
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Background: Treatment with HMG CoA Reductase Inhibitors (statins) decreases cardio-
vascular events and mortality in patients with coronary artery disease (CAD). Little is
known regarding trends in the use of statins in a population-based sample of older
patients surviving acute myocardial infarction (AMI).
Methods and Results: In two national cohorts of 31,399 and 31,759 older patients hospi-
talized between 1998-9 and 2000-1 with confirmed AMI, we identified patients who sur-
vived to discharge. We assessed change in rates of use of statins at discharge in ‘ideal
candidates’ without contraindications to statins. Overall, 27.5% and 46.2% of patients
were discharged in 1998-9 and 2000-1, respectively. Of those patients with an LDL-c
greater than the guideline-based threshold of 130 mg/dL, 55% received lipid-lowering
therapy in 1998-9 compared to 71% in 2000-1. In general, women and the elderly were
consistently less likely to receive statins on discharge.
Conclusions: In a national sample of older AMI survivors, significant increases in dis-
charge prescription of statins occurred irrespective of patient age, sex, race and LDL
cholesterol. Despite these increases, a significant proportion of older patients do not
receive guideline-based lipid management.
1084-179 Ezetimibe/SimvastatinTherapy Is More Effective Than 
Simvastatin Alone at Reducing Remnant-Like Particle 
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Background: Levels of remnant lipoproteins are independent predictors of future coro-
nary events in patients with coronary artery disease. We evaluated the effects of
ezetimibe/simvastatin (EZE/SIM) combination therapy versus SIM alone on remnant-like
particle cholesterol (RLP-C) in hypercholesterolemic patients.
Methods: After a 6- to 8-wk washout and a 4-wk diet/placebo run-in, 1528 patients with
LDL-C 145 - 250 mg/dL and triglycerides <350 mg/dL, were randomized to one of the fol-
lowing daily treatments for 12 wks: EZE/SIM tablet (10/10, 10/20, 10/40, or 10/80 mg/
mg); SIM alone (10, 20, 40, or 80 mg); EZE 10 mg; or placebo. The primary endpoint was
% change from baseline in LDL-C for pooled EZE/SIM vs pooled SIM alone. RLP-C lev-
els were measured using an immune separation assay.
Results: EZE/SIM produced significantly greater reductions in RLP-C than did SIM alone
(table). For each SIM dose comparison, RLP-C was reduced more by the EZE/SIM com-
bination (range: -31.8% to -47.4%) than by the corresponding dose of SIM alone (range:
-22.5% to -37.5%; p<0.001 for all comparisons). The effects of EZE/SIM on RLP-C were
consistent with the effects on LDL-C (-53.1% vs -39.0%; p<0.001); apolipoprotein B (-
42.4% vs -31.6%; p<0.001); non-HDL-C (-48.7% vs -35.9%; p<0.001); and triglyceride (-
24.3% vs -20.8%; p<0.001).
Conclusion: EZE/SIM in a single tablet (10/10 to 10/80 mg/mg) is more effective than
the corresponding dose of SIM alone in reducing plasma levels of potentially atherogenic
remnant lipoproteins.
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1085-165 Aliskiren, a Novel, Orally Effective Nonpeptide Renin 
Inhibitor, Lowers Blood Pressure After Once-Daily 
Dosing in Marmosets, Rats and Humans
Jeanette M. Wood, Randy L. Webb, Frederic Cumin, Christian R. Schnell, Martin P. 
Bedigian, Novartis Institute for Biomedical Research, Basel, Switzerland, Novartis, East 
Hanover, NJ
Background: Renin inhibitors (RIs) provide an attractive new therapeutic approach to the
treatment of hypertension, as they block the first and rate-limiting step of the renin-angio-
tensin system (RAS). The present study investigates the in vivo effects of aliskiren, the
first of a new class of non-peptide RIs.
Methods: Aliskiren was administered orally to normotensive, sodium-depleted marmo-
sets and to hypertensive (mean systolic BP > 140 mmHg) human patients, and subcuta-
neously to spontaneous hypertensive rats (SHR). In animal studies, changes in mean
arterial pressure (MAP; mean±s.e.mean) and heart rate were measured continuously by
telemetry; 24 h ambulatory BP measurement was used in humans. Plasma renin activity
was measured by antibody trapping assay.
Table. Summary of Endpoints
LS-Mean Percent Change 
from Baseline in:
Period Group Treatment n available 
for analysis†
LDL-C HDL-C
1 1 Atorvastatin 10 mg 250 –37.2 5.1
2 Ezetimibe/Simvastatin 
10 mg
252 –46.1‡ 8.0‡
3 Ezetimibe/Simvastatin 
20 mg
253 –50.3‡ 9.5‡
2 1 Atorvastatin 20 mg 235 –44.3 6.9
2 Ezetimibe/Simvastatin 
20 mg
239 –50.2‡ 9.0
3 Ezetimibe/Simvastatin 
40 mg
243 –54.3‡ 12.4‡
3 1 Atorvastatin 40 mg 228 –49.1 7.8
2&3* Ezetimibe/Simvastatin 
40 mg
466 –55.6‡ 11.4‡
4 1 Atorvastatin 80 mg 223 –52.5 6.5
2&3* Ezetimibe/Simvastatin 
80 mg
441 –59.4‡ 12.3‡
LS means and p-values are from analysis of variance model with terms for treatment 
and baseline LDL-C strata. †Baseline values for LDL-C (mg/dL) were: (Group 1, 180.6; 
Group 2, 180.0; Group 3, 179.2), for HDL-C: (Group 1, 46.9; Group 2, 46.6; Group 3, 
46.8). ‡p_0.01 for difference with Atorvastatin in the specified period.
*Treatment Groups 2 and 3 combined in Periods 3 and 4.
Rates of Statin Use in Older AMI Survivors
1998-9
N =14,808
%
2000-1
N =14,606
%
Overall Use 27.5 46.2
Age >/= 75 years * 21.6 40.1
LDL <100 mg/dL 28.8 47.4
LDL 100-129 mg/dL 34.7 56.2
LDL >/=130 mg/dL 55.0 71.3
* in ideal patients with LDL-c ³ 130 mg/dL
Effect of Treatment on RLP-C
Pbo
(N=141)
EZE 10 mg
(N=144)
Pooled
SIM
(N=597)
Pooled
EZE/SIM
(N=570)
Baseline RLP-C (mg/dL) 13.3 14.0 14.0 14.0
% Change from baseline 5.4 -15.6^ -29.31^ -40.6*^
*p<0.001 versus Pooled SIM; ^p<0.001 versus Pbo
RLP-C: remnant-like particle cholesterol; Pbo: placebo; EZE: ezetimibe; SIM: 
simvastatin
